Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

Inclusion Criteria: * Signed written informed consent * Patients with recurrent, diffuse intrinsic pontine gliomas * Patients should have had 2 of the following 3 neurological symptoms: cranial nerve deficit, long tract signs, ataxia and a onset prior to initial diagnosis \< 6 months. * Evidence of disease progression * Have a Lansky or Karnofsky Performance Status of \> 40 * Be between the age \>3 years to \< 18 years of age * Have a tumor that is measurable radiologically * For female patients of childbearing age: presence of a negative pregnancy test within 7 days prior to day 0. * Use of effective contraception * Adequate hematological, renal, and hepatic function Exclusion Criteria: * A history of prior use of EGFR-targeting agents (monoclonal antibodies, tyrosine kinase inhibitors) * More than one line of treatment * Patients with disseminated disease are not eligible * Had radiation therapy completed within 12 weeks of enrollment * Previous chemotherapy completed \< 2 weeks prior to enrollment * If female, is pregnant or lactating * Has other existing serious medical conditions * Has any condition, therapy, or medical condition, which, in the opinion of the attending physician could represent a risk for the patient or adversely affect the study objectives * Is currently taking or planning to take other investigational drugs during the study * Known contraindications against antibodies